Abstract
Offspring of women with epilepsy (WWE) on AEDs are at increased risks for major congenital malformations and reduced cognition. They may be at risk for other adverse neonatal outcomes. Women with epilepsy on carbamazepine (CBZ), lamotrigine (LTG), phenytoin (PHT), or valproate (VPA) monotherapy were enrolled in a prospective, observational, multicenter study of the neurodevelopmental effects of AEDs. The odds ratio for small for gestational age (SGA) was higher for VPA vs. PHT, VPA vs. LTG, and CBZ vs. PHT. Microcephaly rates were elevated to 12% for all newborns and at 12. months old, but normalized by age 24. months. Reduced Apgar scores occurred more frequently in the VPA and PHT groups at 1. min, but scores were near normal in all groups at 5. min. This study demonstrates increased risks for being born SGA in the VPA and CBZ groups, and transiently reduced Apgar scores in the VPA and PHT groups. Differential risks among the AEDs can help inform decisions about AED selection for women during childbearing years.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 449-456 |
| Number of pages | 8 |
| Journal | Epilepsy and Behavior |
| Volume | 24 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 1 2012 |
Keywords
- Antiepileptic drugs
- Apgar
- Epilepsy
- Microcephaly
- Neonatal
- Observational cohort study
- Pregnancy
- Seizures
- Small for gestational age (SGA)
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
- Behavioral Neuroscience
Access to Document
Fingerprint Dive into the research topics of 'Differential effects of antiepileptic drugs on neonatal outcomes'. Together they form a unique fingerprint.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Differential effects of antiepileptic drugs on neonatal outcomes. / Pennell, P. B.; Klein, A. M.; Browning, N.; Baker, G. A.; Clayton-Smith, J.; Kalayjian, L. A.; Liporace, J. D.; Privitera, M.; Crawford, T.; Loring, D. W.; Meador, K. J.; Labiner, David; Moon, Jennifer; Sherman, Scott; Cantrell, Deborah T.C.; Silver, Cheryl; Goyal, Monisha; Schoenberg, Mike R.; Pack, Alison; Palmese, Christina; Echo, Joyce; Meador, Kimford J.; Loring, David; Pennell, Page; Drane, Daniel; Moore, Eugene; Denham, Megan; Epstein, Charles; Gess, Jennifer; Helmers, Sandra; Henry, Thomas; Motamedi, Gholam; Flax, Erin; Bromfield, Edward; Boyer, Katrina; Dworetzky, Barbara; Cole, Andrew; Halperin, Lucila; Shavel-Jessop, Sara; Barkley, Gregory; Moir, Barbara; Harden, Cynthia; Tamny-Young, Tara; Lee, Gregory P; Penovich, Patricia; Minter, Donna; Moore, Layne; Murdock, Kathryn; Liporace, Joyce; Wilcox, Kathryn; Kanner, Andres; Nelson, Michael N.; Rosenfeld, William; Meyer, Michelle; Clayton-Smith, Jill; Mawer, George; Kini, Usha; Martin, Roy; Privitera, Michael; Bellman, Jennifer; Ficker, David; Baade, Lyle; Liow, Kore; Booth, Alison; Bromley, Rebecca; Casswell, Miranda; Barrie, Claire; Ramsay, Eugene; Arena, Patricia; Kalayjian, Laura; Heck, Christianne; Padilla, Sonia; Miller, John; Rosenbaum, Gail; Wilensky, Alan; Constantino, Tawnya; Smith, Julien; Adab, Naghme; Veling-Warnke, Gisela; Sam, Maria; O'Donovan, Cormac; Naylor, Cecile; Nobles, Shelli; Santos, Cesar; Holmes, Gregory L.; Druzin, Maurice; Morrell, Martha; Nelson, Lorene; Finnell, Richard; Yerby, Mark; Adeli, Khosrow; Wells, Peter; Browning, Nancy; Blalock, Temperance; Crawford, Todd; Hendrickson, Linda; Jolles, Bernadette; Kunchai, Meghan Kelly; Loblein, Hayley; Ogunsola, Yinka; Russell, Steve; Winestone, Jamie; Wolff, Mark; Zaia, Phyllis; Zajdowicz, Thad.
In: Epilepsy and Behavior, Vol. 24, No. 4, 01.08.2012, p. 449-456.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Differential effects of antiepileptic drugs on neonatal outcomes
AU - Pennell, P. B.
AU - Klein, A. M.
AU - Browning, N.
AU - Baker, G. A.
AU - Clayton-Smith, J.
AU - Kalayjian, L. A.
AU - Liporace, J. D.
AU - Privitera, M.
AU - Crawford, T.
AU - Loring, D. W.
AU - Meador, K. J.
AU - Labiner, David
AU - Moon, Jennifer
AU - Sherman, Scott
AU - Cantrell, Deborah T.C.
AU - Silver, Cheryl
AU - Goyal, Monisha
AU - Schoenberg, Mike R.
AU - Pack, Alison
AU - Palmese, Christina
AU - Echo, Joyce
AU - Meador, Kimford J.
AU - Loring, David
AU - Pennell, Page
AU - Drane, Daniel
AU - Moore, Eugene
AU - Denham, Megan
AU - Epstein, Charles
AU - Gess, Jennifer
AU - Helmers, Sandra
AU - Henry, Thomas
AU - Motamedi, Gholam
AU - Flax, Erin
AU - Bromfield, Edward
AU - Boyer, Katrina
AU - Dworetzky, Barbara
AU - Cole, Andrew
AU - Halperin, Lucila
AU - Shavel-Jessop, Sara
AU - Barkley, Gregory
AU - Moir, Barbara
AU - Harden, Cynthia
AU - Tamny-Young, Tara
AU - Lee, Gregory P
AU - Penovich, Patricia
AU - Minter, Donna
AU - Moore, Layne
AU - Murdock, Kathryn
AU - Liporace, Joyce
AU - Wilcox, Kathryn
AU - Kanner, Andres
AU - Nelson, Michael N.
AU - Rosenfeld, William
AU - Meyer, Michelle
AU - Clayton-Smith, Jill
AU - Mawer, George
AU - Kini, Usha
AU - Martin, Roy
AU - Privitera, Michael
AU - Bellman, Jennifer
AU - Ficker, David
AU - Baade, Lyle
AU - Liow, Kore
AU - Booth, Alison
AU - Bromley, Rebecca
AU - Casswell, Miranda
AU - Barrie, Claire
AU - Ramsay, Eugene
AU - Arena, Patricia
AU - Kalayjian, Laura
AU - Heck, Christianne
AU - Padilla, Sonia
AU - Miller, John
AU - Rosenbaum, Gail
AU - Wilensky, Alan
AU - Constantino, Tawnya
AU - Smith, Julien
AU - Adab, Naghme
AU - Veling-Warnke, Gisela
AU - Sam, Maria
AU - O'Donovan, Cormac
AU - Naylor, Cecile
AU - Nobles, Shelli
AU - Santos, Cesar
AU - Holmes, Gregory L.
AU - Druzin, Maurice
AU - Morrell, Martha
AU - Nelson, Lorene
AU - Finnell, Richard
AU - Yerby, Mark
AU - Adeli, Khosrow
AU - Wells, Peter
AU - Browning, Nancy
AU - Blalock, Temperance
AU - Crawford, Todd
AU - Hendrickson, Linda
AU - Jolles, Bernadette
AU - Kunchai, Meghan Kelly
AU - Loblein, Hayley
AU - Ogunsola, Yinka
AU - Russell, Steve
AU - Winestone, Jamie
AU - Wolff, Mark
AU - Zaia, Phyllis
AU - Zajdowicz, Thad
N1 - Funding Information: Dr. Pennell receives salary support for research from the National Institutes of Health, the Milken Family Foundation, and the Epilepsy Foundation. She has received travel reimbursement from the National Institutes of Health, the Milken Family Foundation, the Epilepsy Foundation, American Epilepsy Society, and the National EpiFellows Foundation. She has received an honorarium for speaking from Atlantic Health. She also serves as a volunteer member of the American Epilepsy Society Board of Directors, the Epilepsy Research Foundation, the Professional Advisory Board for the Epilepsy Foundation, and on the editorial boards for Epilepsy Currents. Autumn M. Klein, M.D., PhD has received research support from the American Epilepsy Society, the Epilepsy Foundation and Brigham and Women's Hospital, and payment from Digitrace for EEG interpretations. Nancy Browning, PhD has received salary support for research from the National Institutes of Health. Gus Baker, PhD has received educational grants from Epilepsy Research UK, Sanofi Aventis, and UCB, research support from the Medical Research Council and National Institutes of Health, and travel support from GlaxoSmithKline; he has received payment for serving as an expert witness in litigation related to neurodevelopmental effects of antiepileptic drugs and his institution has received compensation for his lectures from UCB. Jill Clayton-Smith, M.D. has received research support from the National Institutes of Health, the Manchester NIHR Biomedical Research Centre, and Action Medical Research, and has received payments to her institution for legal reports and for serving as an editor for the Clinical Dysmorphology journal. Laura A. Kalayjian, M.D. has received research support from the National Institutes of Health, and payment for lectures for GlaxoSmithKline. Joyce D. Liporace, M.D. has received research support from the National Institutes of Health and Marinus Pharmaceuticals, consulting honorarium from GlaxoSmithKline, and payment for lectures from UCB Pharma. Michael Privitera, M.D. has received research support from the National Institutes of Health, Eisai, UCB, American Epilepsy Society, Ortho McNeil, and payment to his institution for his lectures from UCB and GlaxoSmithKline, and travel reimbursement from the National Epifellows Foundation. Todd Crawford, M.S. has nothing to disclose. David W. Loring, PhD has received research support from the National Institutes of Health, Myriad Pharmaceuticals, SAM Technology, Novartis, and consultant fees from UCB Pharma and Neuropace. Dr. Meador reports receiving research support from the GlaxoSmithKline, EISAI Medical Research, Myriad Pharmaceuticals, Marinus Pharmaceuticals, NeuroPace, Pfizer, SAM Technology, Schwartz Biosciences, and UCB Pharma, the Epilepsy Foundation, and the NIH; received salary support to Emory University from the Epilepsy Consortium for research consultant work related for NeuroPace, Upsher-Smith, and Vivus; served as a consultant for Eisai, GlaxoSmithKline, Johnson and Johnson (Ortho Mc Neil), Medtronics Spherics, and UCB Pharma, but the money went to a charity of the company's choice; received travel support from Sanofi Aventis; and also serves on the Professional Advisory Board for the Epilepsy Foundation and the editorial boards for Cognitive and Behavioral Neurology, Epilepsy & Behavior, Neurology, and Journal of Clinical Neurophysiology.
PY - 2012/8/1
Y1 - 2012/8/1
N2 - Offspring of women with epilepsy (WWE) on AEDs are at increased risks for major congenital malformations and reduced cognition. They may be at risk for other adverse neonatal outcomes. Women with epilepsy on carbamazepine (CBZ), lamotrigine (LTG), phenytoin (PHT), or valproate (VPA) monotherapy were enrolled in a prospective, observational, multicenter study of the neurodevelopmental effects of AEDs. The odds ratio for small for gestational age (SGA) was higher for VPA vs. PHT, VPA vs. LTG, and CBZ vs. PHT. Microcephaly rates were elevated to 12% for all newborns and at 12. months old, but normalized by age 24. months. Reduced Apgar scores occurred more frequently in the VPA and PHT groups at 1. min, but scores were near normal in all groups at 5. min. This study demonstrates increased risks for being born SGA in the VPA and CBZ groups, and transiently reduced Apgar scores in the VPA and PHT groups. Differential risks among the AEDs can help inform decisions about AED selection for women during childbearing years.
AB - Offspring of women with epilepsy (WWE) on AEDs are at increased risks for major congenital malformations and reduced cognition. They may be at risk for other adverse neonatal outcomes. Women with epilepsy on carbamazepine (CBZ), lamotrigine (LTG), phenytoin (PHT), or valproate (VPA) monotherapy were enrolled in a prospective, observational, multicenter study of the neurodevelopmental effects of AEDs. The odds ratio for small for gestational age (SGA) was higher for VPA vs. PHT, VPA vs. LTG, and CBZ vs. PHT. Microcephaly rates were elevated to 12% for all newborns and at 12. months old, but normalized by age 24. months. Reduced Apgar scores occurred more frequently in the VPA and PHT groups at 1. min, but scores were near normal in all groups at 5. min. This study demonstrates increased risks for being born SGA in the VPA and CBZ groups, and transiently reduced Apgar scores in the VPA and PHT groups. Differential risks among the AEDs can help inform decisions about AED selection for women during childbearing years.
KW - Antiepileptic drugs
KW - Apgar
KW - Epilepsy
KW - Microcephaly
KW - Neonatal
KW - Observational cohort study
KW - Pregnancy
KW - Seizures
KW - Small for gestational age (SGA)
UR - http://www.scopus.com/inward/record.url?scp=84864299256&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864299256&partnerID=8YFLogxK
U2 - 10.1016/j.yebeh.2012.05.010
DO - 10.1016/j.yebeh.2012.05.010
M3 - Article
C2 - 22749607
AN - SCOPUS:84864299256
VL - 24
SP - 449
EP - 456
JO - Epilepsy and Behavior
JF - Epilepsy and Behavior
SN - 1525-5050
IS - 4
ER -